Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Beginning with precursor lesions, aberrant DNA methylation marks the entire spectrum of
prostate cancer progression. We mapped the global DNA methylation patterns in select …

Human cancers almost ubiquitously harbor epigenetic alterations. Although such alterations
in epigenetic marks, including DNA methylation, are potentially heritable, they can also be …

Abstract Purpose: Aside from Gleason sum, few factors accurately identify the subset of
prostate cancer patients at high risk for metastatic progression. We hypothesized that …

Candidate gene-based studies have identified a handful of aberrant CpG DNA methylation
events in prostate cancer. However, DNA methylation profiles have not been compared on a …

Tumor DNA circulates in the plasma of cancer patients admixed with DNA from
noncancerous cells. The genomic landscape of plasma DNA has been characterized in …

Although prostate cancer (PCa) is the second leading cause of cancer death among men
worldwide, not all men diagnosed with PCa will die from the disease. A critical challenge …

Metastatic prostate cancer remains a major clinical challenge and metastatic lesions are
highly heterogeneous and difficult to biopsy. Liquid biopsy provides opportunities to gain …

Despite much evidence on epigenetic abnormalities in cancer, it is currently unclear to what
extent epigenetic alterations can be associated with tumors' clonal genetic origins. Here, we …

BACKGROUND DNA hypermethylation has emerged as a novel molecular biomarker for the
evaluation of prostate cancer diagnosis and prognosis. Defining the specific gene …